Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc. (LYEL): 7 pipeline candidates · 1 upcoming catalyst · ~20 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
19.5 months
D/E 0.28 · 0% dilution
Lead: Phase 3
7 candidates
1 upcoming, next in ~2023d
2 buys · 9 sells (180d)
A transparent, data-derived signal for Lyell Immunopharma, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$316.2M
Cash
$92.4M
Quarterly Burn
$38.5M
Runway
19.5 mo
Revenue
$2K
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| axicabtagene ciloleucel | Phase 3 |
| fludarabine | Phase 1/Phase 2 |
| gcc19cart | Phase 1/Phase 2 |
| impt-314 | Phase 2 |
| lyl273 | Phase 1/Phase 2 |
| lyl314 | Phase 1/Phase 2 |
| rondecabtagene autoleucel | Phase 3 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
71
Total value held
$185.5M
| Holder | Shares | Value |
|---|---|---|
| arch venture management, llc | 3,247,162 | $65.1M |
| vanguard capital management llc | 1,436,310 | $28.8M |
| orland properties ltd | 754,698 | $15.1M |
| millennium management llc | 458,905 | $9.2M |
| citadel advisors llc | 393,462 | $7.9M |
| venbio partners llc | 337,697 | $6.8M |
| susquehanna international group, llp | 310,198 | $6.2M |
| alphabet inc. | 293,256 | $5.9M |
| blackrock, inc. | 191,820 | $3.8M |
| geode capital management, llc | 166,980 | $3.4M |
Showing top 10 of 71 institutional holders of Lyell Immunopharma, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Lyell Immunopharma, Inc.'s pipeline?
Lyell Immunopharma, Inc. (LYEL) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Lyell Immunopharma, Inc.'s lead drug candidate?
Lyell Immunopharma, Inc.'s most advanced tracked candidate is axicabtagene ciloleucel (Phase 3) for Large B-cell Lymphoma.
What is Lyell Immunopharma, Inc.'s next catalyst?
Lyell Immunopharma, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Randomized Controlled Trial of Rondecabtagene Autoleucel , an Autologous, Dual-targeting C" — expected January 1, 2032.
What is Lyell Immunopharma, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Lyell Immunopharma, Inc. has approximately 19.5 months of cash runway.
What is Lyell Immunopharma, Inc.'s market capitalization?
Lyell Immunopharma, Inc.'s market capitalization is approximately $316.2M.
Get the full picture on Lyell Immunopharma, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.